Structural basis of Keap1 interactions with Nrf2.
Canning P, Sorrell FJ, Bullock AN. · 2015
Read Structural basis of Keap1 interactions with Nrf2. by Canning P, Sorrell FJ, Bullock AN. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4668279.txt.
Introduction
Peter Canning, Fiona J. Sorrell, and Alex N. Bullock published a 2015 review of the structural basis of Keap1 interactions with Nrf2. Keap1 normally targets the stress-response switch Nrf2 for destruction. When oxidative stress disables Keap1, Nrf2 accumulates and switches on protective genes. Drug developers chase this system for diseases from nerve degeneration to cancer. The review appeared in Free Radical Biology and Medicine.
Crystal structures now cover Keap1 alone and bound to its partners: the Cul3 scaffold, the Nrf2 substrate, and small-molecule blockers. Together they explain how Nrf2 binds at two sites and is marked efficiently for disposal. That three-dimensional model gives medicinal chemists a rational base for designing blockers that free Nrf2 on demand.
Catalog record
| CREATOR | Canning P, Sorrell FJ, Bullock AN. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Structural basis of Keap1 interactions with Nrf2 By Peter Canning, Fiona J Sorrell, Alex N Bullock Published in: Free Radical Biology & Medicine DOI: 10.1016/j.freeradbiomed.2015.05.034 ABSTRACT Abstract Keap1 is a highly redox-sensitive member of the BTB-Kelch family that assembles with the Cul3 protein to form a Cullin–RING E3 ligase complex for the degradation of Nrf2. Oxidative stress disables Keap1, allowing Nrf2 protein levels to accumulate for the transactivation of critical stress response genes. Consequently, the Keap1–Nrf2 system is extensively pursued for the development of protein–protein interaction inhibitors that will stabilize Nrf2 for therapeutic effect in conditions of neurodegeneration, inflammation, and cancer. Here we review current progress toward the structure determination of Keap1 and its protein complexes with Cul3, Nrf2 substrate, and small-molecule antagonists. Together the available structures establish a rational three-dimensional model to explain the two-site binding of Nrf2 as well as its efficient ubiquitination. Keywords: Keap1, Nrf2, BTB, Kelch, Cullin, Ubiquitin, Free radicals INTRODUCTION Nrf2, encoded by the gene NFE2L2[1], belongs to the Cap’n’Collar (CNC) subfamily of basic leucine zipper (bZIP) transcription factors, which in vertebrates comprises NFE2 (nuclear factor erythroid-derived 2) and the NFE2-related factors Nrf1, Nrf2, and Nrf3 [2]. Nrf2 has become the best known family member for its cytoprotective role in the responses to oxidative and electrophilic stress [3], [4], [5]. This activity is dependent on its transactivation function and its dimerization with members of the small Maf (musculoaponeurotic fibrosarcoma oncogene homolog) protein family [6]. The Nrf2–Maf heterodimer is targeted specifically to genes containing antioxidant-response elements in their regulatory regions, including many antioxidant and detoxification enzymes, ABC transporters, and other stress response proteins [7], [8]. Under normal conditions, the levels of Nrf2 protein are kept low by the E3 ubiquitin ligase Keap1 (Kelch ECH-associating protein 1), which ubiquitinates Nrf2 in the cytoplasm and targets it for degradation by the 26 S proteasome [9], [10], [11], [12], [13], [14], [15]. This constitutive degradation of Nrf2 allows for only the basal expression of its target stress response genes as part of a housekeeping function. However, under conditions of oxidative stress, or in the presence of electrophilic xenobiotics, the activity of Keap1 is diminished and Nrf2 can accumulate in the nucleus where it activates the inducible high expression of its target genes. In this manner, Keap1 functions as a critical sensor of cellular stress. Its high redox sensitivity is determined by a number of cysteine residues that are distributed throughout the Keap1 protein and are vulnerable to oxidation or to covalent modification by electrophiles. Notably, different reactive chemicals appear to target different cysteines in Keap1, giving rise to the concept of a “cysteine code” [4], [16], [17]. Two residues, Cys273 and Cys288, seem essential for Keap1 to control Nrf2 under both basal and stress conditions, whereas Cys151 is primarily required under conditions of stress [18], [19], [20], [21]. Other Keap1 residues, including Cys226, Cys434, and Cys613, seem important for sensing specific toxins. As a master regulator of the antioxidant response, the Keap1–Nrf2 system protects cellular proteins and DNA from oxidative damage caused by reactive oxygen species and electrophiles. In addition, it controls transporters critical for cellular detoxification. Consequently, the Keap1–Nrf2 system has emerged as an important therapeutic target in cancer and neurodegenerative conditions, as well as many autoimmune and inflammatory diseases [2], [4], [5], [16], [22]. Critical for such intervention strategies is a deep understanding of the structure and function of these proteins. Progress in this respect has relied on the definition of the domain architecture of the Keap1 and Nrf2 proteins and the identification of the specific regions mediating their interactions [23]. The Nrf2 protein in humans is 605 amino acids long and contains seven highly conserved regions known as Nrf2-ECH homology (Neh) domains (Fig. 1). Neh1 contains the CNC–bZIP domain, which mediates heterodimerization with Maf [6]. The Neh2 domain contains the two degrons that are specifically bound by Keap1. These are commonly known as the DLG and ETGE motifs after their sequence conservation in the single-letter amino acid code [24]. Two further redox-independent degrons have since been described in Neh6 [25]. These motifs are not recognized by Keap1, but are instead targeted for degradation by the E3 ubiquitin ligase β-TrCP. This alternative pathway is enhanced by the phosphorylation of Nrf2 by glycogen synthase kinase-3β, providing another mechanism for cellular control of Nrf2 activities [26], [27], [28]. The Neh3–5 domains are thought to function in transactivation by binding to various components of the transcriptional apparatus [29], [30]. Conversely, repression of Nrf2 is conferred by the interactions of Neh7 with the DNA-binding domain of retinoic X receptor α [31]. [Figure: Domain architecture of the Keap1 and Nrf2 proteins. Domain boundaries and residue numbers are shown for the human proteins.] Keap1 belongs to the BTB-Kelch family of proteins, which comprises some 50 members variously named as Kelch-like 1–42 (KLHL1–42) or Kelch and BTB domain-containing 1–14 (KBTBD1–14) [32], [33]. All of these proteins assemble with Cullin 3 (herein Cul3) and Rbx1 to form multisubunit Cullin–RING (really interesting new gene) ligases (CRLs) for protein ubiquitination. Keap1 is classified as KLHL19 and comprises three domains spanning some 611 amino acids (Fig. 1). The N-terminal BTB domain is named after the Drosophila proteins Broad complex, Tramtrack, and Bric à brac, in which it was first identified [34]. The BTB domain mediates the homodimerization of Keap1 and contributes additionally to its interaction with Cul3 [35]. A further Cul3 interaction is provided by the 3-box motif, which forms the proximal part of the central intervening region (IVR domain) [32]. The C-terminal Kelch domain is required for substrate capture and can bind separately to the ETGE [36], [37] or DLG [38], [39] motifs of Nrf2. To date there are no available high-resolution structures describing either of the full-length Keap1 or Nrf2 proteins. Nonetheless, a number of crystal structures featuring Keap1, or its BTB-Kelch family homologs, have revealed the molecular mechanisms determining its interactions with Nrf2 substrate or Cul3 protein, as well as the action of chemical inhibitors that stabilize Nrf2 for therapeutic gain. STRUCTURAL BASIS OF NRF2 BINDING TO THE KELCH DOMAIN OF KEAP1 Nuclear magnetic resonance spectroscopy has shown the Neh2 region of Nrf2 to be intrinsically disordered [24], but capable of binding to the full-length Keap1 protein at low nanomolar concentrations (KD value ~5 nM) [24], [40]. This binding was replicated by a 16-residue peptide (AFFAQLQLDEETGEFL) incorporating amino acids 69–84 of Nrf2, which flank the conserved ETGE motif [24]. Subsequently, the molecular nature of this interaction was captured by two high-resolution crystal structures. The structure of the same 16-residue Nrf2 peptide was solved at 1.5- Å resolution in complex with the Kelch domain of human Keap1 [36]. A further structure was solved independently at 1.7- Å resolution comprising the equivalent mouse Kelch domain and a shorter peptide spanning residues 76–84 of Nrf2 [37]. Additionally, crystal structures have been reported for the human and mouse Kelch domains in the absence of ligand [37], [41], [42]. Overall, the Kelch domain contains six Kelch repeats that fold into a six-bladed β-propeller structure [42]. Each blade (I–VI) comprises a four-stranded antiparallel β-sheet (β strands A–D), in which the shorter βA strands form the central core. The final βA strand from the C-terminal region (CTR) closes the propeller by completing